Nanosonics LimitedASX: NAN

Nanosonics CORIS secures second FDA 510(k) clearance

· Issued by Nanosonics Limited via ASX

Filed with ASX · · 1 page · English

Summary by 6ix AI

This clearance includes high-volume colonoscopes and gastroscopes, further advancing Nanosonics' regulatory and commercialization strategy. CEO Michael Kavanagh emphasized the importance of this milestone in broadening the range of endoscopes that can be reprocessed with CORIS.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/nanosonics-coris-secures-second-fda-510k-clearance-1

Watch Nanosonics' latest callNanosonics (ASX:NAN) Q2 2026 Earnings Call · Replay · Feb 23

Release

11 November 202 6 Nanosonics’ CORIS® secures second FDA 510(k) clearance for expanded endoscope indications Nanosonics Limited (ASX: NAN), a leader in infection prevention solutions, today announces the United States Food and Drug Administration (FDA) has granted a second 510(k) clearance for...

Nanosonics Limited on 6ix

Story so far

Earlier from Nanosonics

All Nanosonics news releases